红霉素联合小剂量茶碱治疗重度慢性阻塞性肺疾病稳定期的临床疗效

Clinical effect of erythromycin combined with low-dose theophylline for stable stage of severe chronic obstructive pulmonary disease

目的探讨红霉素联合小剂量茶碱治疗重度慢性阻塞性肺疾病(COPD)稳定期的临床疗效。方法选取高州市第二人民医院2017年8月—2018年6月收治的重度COPD稳定期患者90例,采用随机数字表法分为A组、B组、C组,各30例。A组给予茶碱缓释片治疗,B组给予红霉素片治疗,C组给予茶碱缓释片联合红霉素片治疗,3组均连续治疗6个月。比较3组治疗前后第一秒用力呼气容积占预计值百分比(FEV1%)、FEV1/用力肺活量(FEV1/FVC)、白介素6(IL-6)、白激素12(IL-12)、白介素32(IL-32)和肿瘤坏死因子α(TNF-α),并比较3组不良反应发生率。结果治疗前3组FEV1%、FEV1/FVC、IL-6、IL-12、IL-32、TNF-α比较,差异无统计学意义(P>0.05);治疗后A组、B组FEV1%、FEV1/FVC、IL-6、IL-12、IL-32、TNF-α比较,差异无统计学意义(P>0.05),C组FEV1%、FEV1/FVC高于A组、B组,IL-6、IL-12、IL-32、TNF-α低于A组、B组(P<0.05)。3组不良反应发生率比较,差异无统计学意义(P>0.05)。结论红霉素联合小剂量茶碱治疗重度COPD稳定期患者的临床疗效确切,可有效改善患者肺功能和炎性因子,且安全性较高。

Objective To investigate the clinical effect of erythromycin combined with low-dose theophylline for stable stage of severe chronic obstructive pulmonary disease(COPD).Methods A total of 90 cases of patients with stable stage of severe COPD were selected from August 2017 to June 2018 in the Second People’s Hospital of Gaozhou,which were divided into A group,B group and C group according to random number table,with 30 cases each.A group was treated with theophylline sustained-release tablets,B group with Erythromycin Tablets,C group with theophylline sustained-release tablets combined with Erythromycin Tablets,three groups were treated for 6 months.The FEV1%,FEV1/FVC,IL-6,IL-12,IL-32 and TNF-αin the first second before and after treatment were compared among the three groups,and the incidence rate of adverse reactions was compared.Results There was no significant difference in FEV1%,FEV1/FVC,IL-6,IL-12,IL-32 and TNF-αamong the three groups before treatment(P>0.05);there was no significant difference in FEV1%,FEV1/FVC,IL-6,IL-12,IL-32 and TNF-αbetween A group and B group(P>0.05);FEV1%,FEV1/FVC of C group were higher than A group and B group,IL-6,IL-12,IL-32 and TNF-αwere lower than A group and B group(P<0.05).There was no significant difference in the incidence rate of adverse reactions among the three groups(P>0.05).Conclusion Erythromycin combined with low-dose theophylline for stable stage of severe COPD patients clinical efficacy is accurate,it can effectively improve the lung function and inflammatory factors,and with high safety.